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We have adopted the murine mammary  tumor model to explore the feasibility 
of using plasma concentrations of a  viral protein to assess the presence and 
status of a solid tumor. As a necessary prelude, a convenient  affinity chromatog- 
raphy procedure was devised (1) for the isolation in good yields of the 52,000 
dalton glycoprotein (gp52)  1 of the mouse mammary tumor virus (MMTV). The 
availability of the pure protein made it possible to develop (1) a radioimmune 
assay (RIA) sufficiently sensitive and accurate for measurement of gp52 in the 
plasma at levels down to 0.1 ng/100 ~l. 
Application  of this  assay in  a  study  (2)  of tumor-free and tumor-bearing 
individuals revealed the following features of the relation between mammary 
tumors and plasma antigen: (a) tumor-bearing animals, male or female, show 
markedly elevated (100-1,000 ng/ml) levels of gp52 as a free soluble protein in 
the plasma and the mean concentration increases with average tumor size; (b) 
the presence of another malignancy (leukemia) does not result in any change of 
this protein in the blood; (c) mammary  tumor tissue located (by transplantation) 
outside the mammary gland is also detected by high plasma gp52; (d) low (2-10 
ng/ml)  plasma  levels  of gp52 are  found  in  tumor-free mice,  whether they 
originate from strains characterized by high or low frequencies of spontaneous 
mammary tumors; (e) tumor-free lactating females exhibit the normally low 
levels of plasma gp52 despite the fact that their milk contains an average of 
20,000 ng/ml of this protein; and finally, (f) the circulatory clearance time of 
gp52 in tumorous animals is sufficiently rapid (a half-life of 4-6 h) to suggest a 
requirement for continued replenishment to maintain the high levels observed. 
The rapid clearance time and the other features noted offer the intriguing 
possibility that plasma levels of gp52 may be useful as specific and responsive 
indicators of the presence and extent of murine mammary neoplasia. It is the 
purpose of the present investigation to subject this expectation to further test by 
examining the effect of surgical removal of tumor on the gp52 levels in the 
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Program Contract NO1-1-1010, and Contract NO1-CM-67081 of the Division of Cancer Treatment 
of the National Cancer Institute. 
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circulation.  If the  tumor  is  the  sole  or  principal  source  of the  plasma  gp52, 
excision should lead to a  drop in its level. If the expected decrease does occur, an 
opportunity  is provided that  is of even greater  interest  for monitoring  disease 
status.  Animals  can  be  followed postoperatively  for  periods sufficient  for the 
occurrence of relapse to determine  when  and how the gp52 returns  to its high 
presurgical levels. 
In particular, the present investigation was designed to answer the following 
questions:  (a)  What  is the  effect of tumor  excision on  the  circulating  level of 
gp52?  (b)  Can  regrowth  or new  primaries  during  the  postoperative  period be 
detected  by  rises  in  the  gp52  plasma  levels?  (c)  More  importantly,  can  the 
behavior of the gp52 level signal the recurrence of a  tumor before it is detectable 
by palpation? (d) When individual mice are compared during periods of relapse, 
are the  gp52  levels per unit  mass  of developing tumors  the  same  or different 
from one mouse to another? 
The data obtained provide answers to these questions and offer evidence that 
the plasma levels of gp52 do provide information on tumor  status that is of both 
diagnostic and prognostic value. 
Materials  and  Methods 
Mouse Strain.  MMTV-infected hybrid (BALB/c ×- DBA/8) F~ mice, designated by CD8F1 were 
obtained and  used,  as  previously described  (2,  3),  as  a  convenient  source  of autochthonous 
spontaneous mammary tumors. CDSF1 females were selected for all the experiments described. It 
should  be  noted  that  the  use  of animals  with  single tumors  does  not  eliminate the  likely 
appearance of a new primary tumor in one of the nine other apparently nondiseased breasts during 
the course of the experiments. 
Surgical  Procedures.  Three  surgical procedures were  used,  all under  general  anesthesia 
(sodium pentebarbitol). One is a  "sham" operation consisting of an incision around the tumor, 
which is left in place. Another is a "strip" or enucleative removal. Here a longitudinal incision is 
made through the skin and the subcutaneous tissue adjacent to the tumor. The tumor-bearing skin 
flap is then mobilized laterally and the tumor enucleated from its subcutaneous attachment by 
blunt dissection. After the area is sponged, the skin flaps are closed with metallic clips. This 
procedure often leaves behind microscopic tumor foci that usually regrow, and thereby furnishes 
an excellent experimental model of  minimal residual disease for the study oftumor recurrence. 
Finally, we have the "radical" excision in which the skin is incised in an elliptical fashion 
around the tumor leaving a  margin of clearly uninvolved normal skin attached to the tumor. 
Mobilization of skin, tumor, and fat pad is begun cephalad and carried toward the inguinal or 
axillary region with en bloc dissection of the regional lymph nodes. Radical surgery, in contrast to 
strip enucleation, is often locally curative. 
Blood Samples.  Approximately 500 ~1 were removed about every 2 wk from the retro-orbital 
venus plexus, using heparinized tubes. Plasmas were separated from cells by low speed centrifu- 
gation, frozen rapidly in a dry ice methanol bath, and then stored at -70°C until subjected to 
radioimmunoassay. 
Radioimmunoassay  (RIA) of MMTV gp52.  The MMTV  gp52,  purified by concanavalin A 
affinity chromatography and iodinated with  ~25I-Bolten-Hunter  reagent,  was used for RIA as 
previously described (1). The assay is a blocking radioimmunoassay in which delayed addition of 
the labeled antigen is employed to maximize the sensitivity of the measurement. 
Determination of Tumor  Weight.  The weights of tumors were determined using one of the 
following alternative procedures: (a) When the tumors were surgically removed their weights 
were determined gravimetrically. (b) If left in place, tumors were measured at each palpation 
with calipers (two perpendicular measurements). The weights were then estimated (4) in milli- 
grams from the relation 0.4 (L × W2), where L and W represent, respectively, the length and width 
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Results 
The  collaborative  experiments  to  be  described  had  a  useful  double-blind 
component.  All of the surgical procedures and diagnostic palpations for tumor 
presence  were  carried  out  at  the  Catholic  Medical  Center  of Brooklyn  and 
Queens. All of the blood samples were coded and then sent for gp52 analysis to 
the laboratories at the Institute  of Cancer  Research of Columbia University. 
The  virtually  complete  concordance  under  these  circumstances  between the 
clinical evaluations and the gp52 levels added further confidence to the validity 
of the conclusions deduced. 
The Effect of Tumor Removal on Plasma gp52.  We first performed a limited 
experiment designed to test the feasibility of the whole approach by probing the 
following issues: (a) Does the gp52 plasma level in fact drop on tumor removal? 
(b) If it does fall, how far and how fast? (c) What happens postsurgically to the 
gp52 levels with particular reference to tumor recurrence? (d) Does the particu- 
lar surgical procedure used have  an effect on the subsequent behavior of the 
plasma gp52? 
15  tumor-bearing  animals  were  divided  into  three  groups  of 5  each  and 
subjected to the surgical procedures described in Materials and Methods. These 
include the sham control operation,  which leaves the tumor in place, the strip 
method, which is a  simple enucleation of the tumor,  and the radical procedure 
intended to achieve a local "cure." Blood samples for gp52 analysis were taken 1 
day before surgery and postsurgically at 2-wk intervals.  Here we may note a 
restraint  that  limits the  amount  of information  attainable  in  actual  practice 
with the mouse system. To insure the quantitative reliability of our gp52 assays 
we performed a  three point titration  with varying amounts of plasma,  which 
requires  a  sample  size of between 200  and  500  ~l at each bleeding.  To avoid 
imposing an unacceptable strain on the animals in the postsurgical period, blood 
samples  were  taken  no  more  often  than  every  2  wk,  even  though  a  more 
frequent sampling would have been prognostically more informative in view of 
the comparatively rapid progress of this disease in the mouse. 
The gp52 plasma levels were followed for a period of 3 mo after surgery, and 
the findings in the individual mice are detailed in Fig. 1 as a semilog plot of the 
plasma concentration of gp52 versus time. Solid symbols indicate the presence of 
a palpable tumor, and the open symbols signify that no tumor could be detected 
by palpation at the time the blood sample was taken. 
The  solid  horizontal  line  at  2.5  ng/ml  in  Fig.  1  marks  the  level  of gp52 
observed (2) in normal mice. The dashed line, corresponding to a level of 40 ng! 
ml, of Fig.  1 was drawn for its comparative convenience in this experiment.  It 
will be noted that all animals having values significantly above 40 ng/ml had 
palpable  tumors,  whereas  those  with  plasma  concentrations  below this  level 
were free of  tumors detectable by palpation. This fact alone establishes the value 
of the gp52 level as a  signal for the presence of tumor.  However, it should be 
noted immediately that the particular cut-off value of 40 ng!ml cannot be taken 
as an absolute invariant that can serve to distinguish tumorous from nontumor- 
ous individuals for all groups of animals and for all samples of reagents.  In the 
first place, the size of the usable sample (eight animals in all) in this experiment 
is far too inadequate to establish a valid value of this parameter. In addition, we PLASMA  LEVELS  OF  A  VIRAL  PROTEIN  AS  A 
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The concentration of gp52 in the plasma level of individual mice is presented both 
find it necessary to monitor the quantitative properties of every preparation of 
gp52  and its  125I derivative by a  complete titration curve before they can be 
reliably used in a  RIA.  It has been our experience that it is not difficult to 
establish a  reliable cut-off gp52  level with a given set of reagents, but we find 
that the actual value will range between 15 and 40 ng/ml. 
A striking feature of the data described in Fig.  1 is the clear-cut difference 
between the control sham group and the two in which the tumors were surgi- 
cally removed. The average gp52  concentration in the controls rose from the 
presurgical level of 190 ng/ml to over 600 ng/ml in the first 2 wk after surgery. 
Then the average values continued to increase above 1,000 ng/ml until all of  this 
group succumbed to the disease by the 8th wk of the experiment. Two of the 
control individuals experienced moderate transient drops, but none fell below 
the 40 ng/ml characteristic of the tumor-free state. This is in sharp contrast to 
the strip and radical groups in which the tumors were removed at surgery. Both 
FIG.  1. 
before  and  after  surgery.  The  three  groups  are  divided  according  to  type  of  surgery 
performed: sham (tumor left in place), strip (tumor is removed), and radical (tumor, fat pad, 
local lymph nodes, and surrounding skin are removed). Short solid horizontal lines depict 
mean concentrations before and after surgery. The dotted line represents an approximate 
division point betwen tumor-bearing and nontumor-bearing animals with respect to gp52 
plasma concentration. The lower solid line represents the mean concentration for 20 normal 
CO8 mice (10 males and 10 females). Filled symbols indicate the presence of a tumor, while 
open symbols indicate tumor-free animals. A  (t) is used to signify an animal's death, while 
an (*) is used where tumors were clinically detected 4 days after a  plasma determination. 
The double vertical line marks the time of surgery. E.  RITZI,  D.  S.  MARTIN,  R.  L.  STOLFI,  AND  S.  SPIEGELMAN  1003 
of these experienced sharp drops in the first 2 wk after surgery, amounting to 
declines in both instances of between one and two orders of magnitude  in the 
plasma concentrations of gp52. This decline continued in the next 2 wk in those 
animals that had not suffered relapses in the first 2 postsurgical wk. 
The fall in gp52 after removal of tumor obviously provides a positive answer to 
the first question posed and supports the expected relation between tumor and 
plasma  antigen  deduced from our initial  study  (2).  It would appear  that  the 
principal  source of the gp52 found in the plasma  of tumorous animals  is the 
tumor itself. 
The excellent agreement between the clinical and immunological diagnostic 
decisions was made even more gratifying by an apparent exception. One mouse, 
having a gp52 level well below the 40 ng/ml level, was diagnosed by palpation as 
positive for a tumor mass. However, a  more detailed examination revealed the 
presence of a nonmalignant  cyst. 
Several other noteworthy features emerged from these experiments.  Despite 
the limitations imposed by the necessarily infrequent blood sampling, the gp52 
levels yielded some information on clinical status before it became evident from 
physical examination.  Two animals  (starred in Fig.  1) of the strip group were 
diagnosed  as  positive  on  the  basis  of gp52  levels  at  the  fourth  postsurgical 
bleeding although no tumor could be detected at that time on palpation.  How- 
ever, in both instances tumors became palpably evident within the next week. A 
similar situation held true for two animals of the radical group, both of which 
were close to the 40 ng/ml level and were tumor free by palpation at the time. 
The  one  that  was  at  that  stage  by the  second postsurgical  bleeding became 
tumor positive  by palpation  at  the  next  bleeding.  The  other  (starred  at  the 
fourth postsurgical bleeding of the radical group in Fig. 1) developed a palpable 
tumor within 3-4 days after this sample was taken.  It will be seen from Fig.  1 
that two animals of the radical surgery group were the only ones to be cured by 
the surgical procedures. These were also the only ones in which the gp52 plasma 
concentration remained well below the 40 ng/ml for the entire duration of the 
experiment. 
Increases in the plasma gp52 levels were observed in all relapses whether they 
were due to recurrence  at the original  surgical site or to new primary tumors 
elsewhere. It may be seen from Table I that the surgical procedure influenced 
the probability of relapse at the original site, but did not affect the incidence of 
new  primaries.  Thus,  regrowths  occurred  in  three  out  of the  five  animals 
subjected to strip  surgery and  only one such occurred  in the  radical  surgery 
group. The number of new primaries were identical in each. 
Variations in gp52 Levels Versus Tumor Size.  In our previous study (2) we 
noted that there were excellent positive correlations between average tumor size 
and the means of the corresponding plasma concentrations of gp52. However, it 
was evident from the wide scatter of the gp52 levels around the mean values that 
factors other than tumor mass were playing a  role.  The experiments of Fig.  1 
and  Table  I  provided  us  with  an  opportunity  of examining  this  question  in 
greater detail since we automatically accumulated information on tumor mass 
and gp52 concentration for each mouse that suffered relapse.  Some representa- 
tive outcomes are described in Fig. 2 in which both tumor sizes (dotted lines) and 
gp52 concentrations  (solid lines) are plotted as a  function of time after surgery 1004  PLASMA LEVELS OF  A VIRAL PROTEIN AS  A DIAGNOSTIC SIGNAL 
TABLE I 
Disease Status at the End of the Observation Period 
Percent  Percent  Percent  Number of  Number of  cured  at  New pri-  bearing new 
Type of surgery  animals  totally  cured*  regrowths  the site of  maries  primary tu- 
surgery$  mors 
Sham  5  0  0  0  0  0 
Strip  5  0  3  40  2  40 
Radical  5  2  1  80  2  40 
Tumor regrowths, development  of new primary tumors, and "cures" are presented for each form 
of surgery. While no regrowths or new primaries were detected in the control (sham) animals, it 
should be noted that their original spontaneous tumors continued to grow in all cases resulting 
in their ultimate deaths. 
* Animals developing neither a regrowth nor a new primary tumor during the course of the 
observation period. 
The percent of animals free of regrowth at the initial site of surgery. 
for the individual mice indicated by the numbers placed next to the correspond- 
ing curves.  First,  it should be mentioned that in all mice studied,  including 
those  not  detailed  in  Figs.  2  and  3,  increase  of tumor  mass  as  the  disease 
progresses was invariably accompanied by a rising level of gp52. The quantita- 
tive relation between the two, however, fell into three classes. One of these, in 
which the increases in tumor size and antigen levels paralleled each other quite 
well,  is  exemplified by numbers  18,  38,  24,  and  19 of Fig.  2 A.  Fast  growing 
tumors are accompanied by rapid rises in plasma gp52, whereas slow growing 
ones are matched by very gradual increases in this antigen.  A  second type is 
shown by number 63 of Fig. 2 B in which the tumor grew faster than would be 
expected from the  rate of increase in  the  plasma  gp52.  Finally,  the  obverse 
situation appears to hold in the case of number 89 of Fig. 2 A. 
Another informative way to look at  the  relationships between tumor  and 
antigen in individual mice is shown in Fig. 3 where the gp52 plasma concentra- 
tion is plotted against tumor mass. The positive slopes and the shapes observed 
indicate an approximately linear relation between tumor growth and increasing 
levels  of plasma  gp52.  However,  the  differences in  slopes  suggest  that  the 
amount of gp52 produced per unit increment in tumor mass differs from individ- 
ual to individual, a result not unexpected from the rather wide scatter around 
the mean for each tumor size range (2). 
Further Evaluation  of gp52  Plasma  Levels  as  Diagnostic  and  Prognostic 
Indicators of Tumor Status.  The principle purpose of  the experiment described 
in Figs. 1-3 and Table I was to establish whether tumor excision is followed by a 
fall in gp52.  The subsequent behavior of the gp52 in response to new tumors 
predicts  the  potential  usefulness  of plasma  gp52  as  a  diagnostic  device for 
mammary neoplasia.  However, the  numbers of animals  involved were quite 
small,  and  it  was  clearly necessary to  check the  validity of the  diagnostic 
implications by setting up a more extensive experiment with a larger number of 
tumorous animals, all treated alike. On the basis of our preliminary experience 
we elected to employ a  strip surgical removal of the initial tumor, leaving in 
most  cases  microfoci of tumor cells  for  subsequent  regrowth of the  original 
tumor. If new primaries arose elsewhere during the course of the experiment, E.  RITZI,  D.  S. 
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FIG.  2.  Tumor size (dashed lines) and gp52 concentration in plasma (solid lines) are both 
presented as a function of days after surgery. Each mouse is represented with two curves, 
one for tumor size and one for gp52  level. These can be compared by matching mouse 
numbers. Mice presented in  (A)  demonstrate a  close correspondence between increasing 
tumor size and gp52 level, while (B) contains a few mice in which increases in tumor growth 
and antigen level were disproportionate. 
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these would be removed by radical surgery. This strategy is designed to maxi- 
mize the  amount  of information  gained  on the  relations  of the  gp52  level to 
recurrence at the original site. 
45 animals were bled 1 or 2 days before surgery, at 9 days after surgery, and at 
approximately 2-wk intervals thereafter.  The gp52 levels were determined for 
all 45 animals  at each time point.  Examination  for tumors by palpation  and 
their measurements were made about every 3rd day, always including the day of 
the bleeding. 
We present in Fig. 4 a semilog plot of gp52 levels versus time for 10 of the 45 
mice. These individuals were chosen because they exemplify the types of rela- 
tionships  observed between the  gp52  levels  and  tumor  behavior.  Here  open 
symbols refer to animals  free of palpable tumors  and  completely or partially 
filled symbols indicate the presence of tumors at the times indicated. Again, all 
animals experienced a  10-100-fold drop in plasma gp52 levels immediately after 
surgical  removal  of the  tumor.  However,  as  in  the  first  experiment,  three 
strikingly different postsurgical patterns are identifiable in the curves of Fig. 4. 
One group (numbers 1-4) are survivors that remain tumor free throughout the 
experimental  period,  a  feature reflected in their  gp52 plasma concentrations, 
that kept below the 15 ng/ml level. Although only four survivors are described in 
Fig.  4, there were in all  12 such tumor-free survivors with corresponding low 
levels of gp52.  The second group consists of tumorous animals  that were still 
alive at the end of the experiment. Some (e.g., number 5) experienced a relapse 
late  (at the fifth postsurgical bleeding)  and others  (e.g.,  numbers 6 and  7) at 
intermediate  times. In all such cases, recurrence was signaled by a rise in the 
gp52 levels followed by further increases paralleling the progressive regrowth of 1006  PLASMA  LEVELS  OF  A  VIRAL  PROTEIN  AS  A  DIAGNOSTIC  SIGNAL 
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Fro.  3.  gp52 levels are presented as a function of tumor size for six mice. Each postopera- 
tive individual is represented by a different symbol. Differences in the slopes of these lines 
indicate differences in the amount of gp52 detected per unit mass of tumor. 
the  tumor.  In  all,  14  of the  45  mice  showed  this  pattern  of surviving  the 
experiment despite their increasing tumor loads. The third group, exemplified 
by numbers  8-10 of Fig.  4,  are  characterized  by early recurrence  and  death, 
events  clearly  foreshadowed  by a  sharp  rise  in  plasma  gp52  at  the  second 
postsurgical bleeding. There were 16 mice that showed this kind of aggressive 
tumor response. 
The final clinical evaluations taken after 106 days, when the experiment was 
terminated,  are  summarized  in  Table  II.  The  strip  surgery  eliminated  the 
disease for the period of observation in 12 animals  and did not in 31.  Two ani- 
mals  were omitted from the  experiment  because of premature  deaths  not at- 
tributable to tumor recurrence. 
It  is  evident  from  the  10  mice  shown  in  Fig.  4  that  gp52  levels  provide 
information on the clinical status and the progress of the disease in the three 
types represented.  Elevations of gp52 above 30 ng/ml are invariably associated 
with the appearance  of tumors.  Only those that maintained  levels below this 
value remained tumor free. The general validity of this pattern is confirmed by 
the  data  on  all  45  mice  which  are  presented  more  compactly in  Fig.  5  as  a 
semilog scatter plot of gp52 plasma concentrations  versus time after surgery. 
Solid circles and open circles indicate tumor-bearing  and tumor-free animals, 
respectively.  Circles  containing  an  X  identify  tumor-free  animals  that  will 
develop a  palpable tumor by the next bleeding.  The gp52 mean values at the 
various time intervals  are indicated by the horizontal  heavy zigzag lines.  All 
gp52 averages in the postsurgical periods are based on the values obtained from 
the tumor-free members of the group at each time period. Only the presurgical 
average value is determined from animals with tumors. Although not identify- 
ing individual  mice,  this method of presentation  furnishes  an overall view of 
tumor status and gp52 levels and how these change with time within the tumor- 
free population. E.  RITZI,  D.  S.  MARTIN,  R.  L.  STOLFI,  AND  S.  SPIEGELMAN 
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FIG. 4.  gp52  levels have been presented as a semilog plot versus time after strip surgery. 
10 (numbered 1 through 10) of the 45 mice (each represented by a separate symbol) were 
chosen to exemplify  the types of relationships observed  between gp52 levels and the tumor 
status of individual postoperative animals. Filled or partially filled symbols indicate the 
presence of tumor, while open symbols  indicate the absence of a detectable regrowth. The 
double vertical line indicates the time of surgery and a (f) signifies death. 
The average gp52 plasma concentrations underwent the customary 10-100- 
fold fall in the first 9 days after surgery. This decrease continues for the next 4 
wk and is then followed by a  slight rise.  The distribution with respect to the 
means  of the  gp52  values  in  the  postsurgical  intervals have  diagnostic  and 
prognostic significance. Thus, all animals with tumors exhibit gp52 levels well 
above the mean, not a single one falling below these levels. Further, those that 
suffer relapse before the next bleeding interval (crossed circles) tend to cluster 
near or above the mean values, whereas those that remain disease free for the 
next interval (open circles) tend to be found below the mean. 
Table III summarizes these diagnostic features in greater detail by tabulating 
for each time interval the probabilities of an animal having a palpable tumor as 
a function of  its plasma concentration of  gp52. The first 9-day postsurgical period 
is omitted since the time interval is too short for the development of a  tumor 
detectable by palpation. The three gp52 levels used correspond to the means of 
the tumor-free animals at each time interval, twice this mean,  and 30 ng/ml 
which  corresponds to  twice  the  highest  mean  observed in  the  nontumorous 
groups. The 30 ng/ml level alone is used for the presurgical values, and all but 
one (at 25 ftg/ml) of these had gp52 levels above 30 ng/ml. Since the last group 
(at 86 days) had the highest tumor-free mean of 15 ng/ml, we used 15 and 30 ng/ 
ml as the basis of comparison. 
If the gp52 level of any animal fell at 30 ng/ml or above, the probability that it 
had a  tumor was a virtual certainty at all the intervals examined. There were 
only two exceptions in the 94 assays of nontumorous animals with gp52 values 
above 30  ~g/ml.  One was a  mouse that died before the next bleeding and the 
other developed a tumor by the next bleeding. If the gp52 values fell above twice 1008  PLASMA  LEVELS  OF  A  VIRAL  PROTEIN  AS  A  DIAGNOSTIC  SIGNAL 
TABL~  II 
Clinical Evaluation 106 Days after Strip Surgery 
Numberoftu-  Numberoftu-  Numberoftu- 
Percent re-  Number of  Percent 
mor recur-  currence  deaths*  mor-bearing  mor-free sur-  cured$ 
rences  survivors  vivors 
31  68.9  19  14  12  26.7 
The disease status of 45 mice have been evaluated during 106 days after "strip" surgery. The 
number of cures, recurrences, tumor-bearing survivors, and deaths are recorded. 
* Note: two deaths were not directly attributable to tumor recurrence. 
Cured refers to mice free of disease at the end of the observation period. 
the  mean  (at  a  given  interval)  the  probabilities  of having  a  palpable  tumor 
ranged from 0.80 to 1.00.  Finally,  in all the intervals,  if an animal had a  gp52 
value below the mean,  the probability of finding a  detectable tumor was zero. 
There were no exceptions to this rule in the 59 assays falling below the mean. 
The prognostic values of gp52 levels are examined in Table IV which records 
the probabilities of tumor recurrence.  Those with gp52 values above the mean 
have a much greater chance of relapsing in the next 2 wk than those with values 
below the mean.  The last column of Table III calculates the probability that a 
given animal at each time interval either has a tumor or will get one in the next 
2-wk interval.  As might be expected, the relationship to the gp52 value is even 
stronger here than for either one alone.  Thus,  animals  above the mean have 
probabilities ranging from 0.63 to 1.00 of either having a tumor or relapsing with 
one by the time of the next bleeding. 
Table IV considers only the short term likelihoods of a  relapse by predicting 
its occurrence in the next 2-wk interval.  It was of interest to examine whether 
gp52 levels possessed long range  prognostic value and  in particular,  whether 
presurgical levels of gp52 could identify those individuals that would be likely 
candidates for tumor-free survival. This question is examined in Table V where 
we tabulate the probabilities of surgical cures as a function of plasma gp52 levels 
before surgery.  For comparison we also include similar probabilities based on 
the  different  tumor size classes presented  at surgery.  There  were eight mice 
with gp52 plasma concentrations below 100 ng/ml at surgery, and six (or 75%) of 
these  are  to be found among  the  12 tumor-free survivors.  The probability of 
survival without disease drops markedly from 0.75 to 0.18 and 0.14 in the groups 
that  had  between  100  and  3,400  ng/ml  of gp52  in  their  plasmas just before 
surgery.  Rather  surprisingly,  the  probability of tumor-free  survival  does not 
vary significantly with the size of the tumor removed despite the fact that the 
tumor masses range from less than 200 mg to over 2 g. 
It would appear that gp52 plasma levels at surgery are considerably superior 
to tumor mass as a prognostic indicator of a successful surgical cure. While this 
is not an outcome that could have been predicted on any a priori grounds, it was 
logically conceivable in view of the marked variations observed in gp52 plasma 
concentrations per unit mass of tumor. 
Discussion 
Our  immediate  aims were to determine  the effect of tumor excision on the 
plasma  gp52  and  to  follow  the  subsequent  behavior  of the  antigen  in  the E.  RITZI,  D.  S.  MARTIN,  R.  L. 
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Fro.  5.  gp52  levels for each of the  45  mice receiving strip  surgery  are presented  as  a 
semilog scatter plot of gp52 concentration versus time after surgery. Filled symbols indicate 
the presence of tumor while open symbols indicate that animals were tumor free. Symbols 
with an (×) represent nontumor-bearing animals which will suffer recurrence before the 
next bleeding. A  (¢) is utilized to designate the death of one apparently tumor-free animal 
that possessed an abnormally high gp52 level and was a  suspect for a metastatic growth. 
The mean gp52 levels are indicated by heavy zigzag horizontal lines.  Mean values after 
surgery are determined from the nontumorous individuals only. The double vertical line 
denotes the time of surgery. 
postoperative period with particular emphasis on its relation to tumor recur- 
rence. The sharp decrease in the plasma gp52 which attends tumor removal 
identifies the tumor as the principal source of the gp52 required to maintain the 
high levels characteristic of a tumorous animal. The low levels of gp52 found 
after surgery made it possible to achieve our second objective by .providing the 
opportunity to examine the usefulness of gp52 as a detector of relapse. The data 
obtained suggest that  the  plasma concentrations of this  antigen do  in  fact 
measure tumor status as reflected by the following findings: (a) All animals 
with tumors possessed gp52 plasma concentrations well above the mean values 
(6.4-15.7  ng/ml) of the tumor-free animals.  (b)  All tumor recurrences were 
identified by increases in gp52 levels, and some were detected 4-7 days before 
they were found by palpation.  (c) In any given interval, the probability for 
relapse in the next 2 wk is considerably higher for those animals with gp52 
levels above the mean of the tumor-free individuals. (d) Tumor regrowths were 
accompanied by continued increases in plasma gp52 concentrations at rates 
which usually matched the speed of tumor development. (e) The only animals 
that remained tumor free at the end of the 106-day experimental period were 
those that maintained their gp52 levels at or below 15 ng/ml. (/9 Finally, and 
most remarkably, levels of gp52 at the time of surgery are superior to tumor 
loads as prognostic indicators of a successful long-term surgical cure. 
Despite the restrictions imposed by the limited frequency with which blood 
samples can be drawn, clinically useful information can be obtained on tumor 
status in the mouse by following plasma concentrations of gp52. It would appear 1010  PLASMA  LEVELS  OF  A  VIRAL  PROTEIN  AS  A  DIAGNOSTIC  SIGNAL 
TABLE  III 
Antigen Level as an Indicator of Tumor Status 
Days relative to  gp52 values  Probability of having 
surgery  a  tumor 
ng/ml 
-  1  ->30.0  1.00 
23  ->30.0  1.00 
>13.2  0.80 
-<6.6*  0.00 
35  ->30.0  1.00 
->12.8  0.93 
-<6.4*  0.00 
51  ->30.0  0.93 
->21.0  0.88 
-<10.5"  0.00 
70  ->30.0  1.00 
->18.2  1.00 
-<9.1"  0.00 
86 
m 
->30.0  0.91 
-<15.0"  0.00 
* These  are the mean values of the plasma  gp52 concentrations  deter- 
mined from the tumor-free  animals. 
that our goal of  developing a systemic measure of  mammary neoplasias has been 
achieved. 
It  is obviously of pressing  importance to exploit this new methodology by 
determining whether the gp52  assay can be used for monitoring the effective- 
ness of adjuvant chemotherapy. It is conceivable that the data thus generated 
will provide a more rapid and informed estimation of the therapeutic effective- 
ness of new and varied drug combinations than the methods presently in use. 
The fact that gp52  levels at surgery appear to provide better indications than 
tumor mass for the future outcome supports the hope that gp52 concentrations 
will likewise serve as earlier indicators of ultimate success with other therapeu- 
tic modalities. It also suggests the desirability of  testing the effect of presurgical 
chemotherapeutic suppression of the plasma gp52 to levels below 100 ng/ml in 
the hopes of improving the probability of long-term tumor-free survival. 
We  have  already  noted in our previous study  (2)  that although  there is a 
correlation between plasma gp52  and tumor weight,  there are clearly factors 
other than simple tumor mass which play a role in determining the plasma gp52 
concentrations,  a  feature  which  is  clearly  illustrated  by  the  results  of the 
present investigation described in Figs. 2 and 3. It is obviously of urgent interest 
to identify the reasons underlying the variations in gp52 observed per milligram 
of tumor,  particularly since the aggressiveness  of a  tumor may be positively 
related to this ratio. One possible explanation for apparently abnormally high 
rates of gp52 production is the existence of metastatic lesions which would go E.  RITZI,  D.  S.  MARTIN,  R.  L.  STOLFI,  AND  S.  SPIEGELMAN 
TABLE  IV 
Probability Analysis of gp52 Antigen Level as an Indicator of Present and 
Future Tumor Status 
1011 
Probability of re-  Probability of hav- 
Number of days  gp52 values relative  lapse in the next 2  ing a tumor or re- 
postsurgery  to mean*  wk  lapsing in next 2 
wk 
9  >15.7  0.78  0.78 
-<15.7  0.19  0.19 
23  >6.6  0.35  0.72 
-<6.6  0.11  0.11 
35  >6.4  0.33  0.97 
-<6.4  0.05  0.05 
51  >10.5  0.22  0.86 
-<10.5  0.08  0.08 
70  >9.1  0.18  0.63 
-<9.1  0.22  0.22 
86  >15.0  0.67  1.00 
-<15.0  0.00  0.00 
At each time interval  the  animals are divided into  those with gp52 levels  above the 
average and those with concentrations below the average. Probabilities  are then 
estimated for these two groups of suffering a relapse. The last  column uses the 
means of  Table III  to calculate  the combined probabilities  at each time interval  of 
either  having a tumor or relapsing in the next time interval. 
* Means are determined from the tumor-free mice as nanograms per milliliter. 
undetected by the physical examinations  employed.  It will not be difficult to 
obtain  the  relevant  information  on  this  issue  since  in  this  model  natural 
metastases almost always initially involve the lungs.  Whatever the cause, the 
existence of this variability makes it evident that serial assays of individuals for 
plasma  gp52  will  continue  to  provide  the  most  illuminating  information  on 
disease status and its future probable outcome. 
The overall purpose of our earlier investigations (1, 2) and the present one was 
to see whether a  solid tumor associated with a viral agent will release into the 
plasma a viral protein that could serve as a useful monitor of disease status. The 
CDSF1 mouse mammary tumor model was chosen because it has already proven 
(3)  its  value  as  a  predictive  guide  for  exploring  adjuvant  chemotherapeutic 
modalities for the most effective management of human breast cancer. It seems 
likely that  availability of a  specific and sensitive systemic monitor of disease 
status during therapy will serve to augment the future usefulness of the CD8F1 
experimental model. 
The ultimate  reason for studying the mouse mammary tumor model stems 
from the hope that it will generate the technology required for the attempt to 
identify a  correspondingly useful particle-related protein in human breast can- 
cer. That this is not an unreasonable expectation is suggested by our previous 
studies which have shown that human breast tumors contain particles exhibit- 1012  PLASMA  LEVELS  OF  A  VIRAL  PROTEIN  AS  A  DIAGNOSTIC  SIGNAL 
TABLE  V 
Probabilities  of Surgical Cures* Determined from Antigen Levels and Tumor Size at 
Surgery 
gp52 level (ng/ml) at surgery 
(25-100)  (100-300)  (300-3,400) 
Probability  of being  0.75  0.18  0.14 
free of diseases 
Tumor size classes (mg) at surgery 
(69-200)  (200-300)  (300-500)  (500-2,300) 
Probability  of being  0.23  0.36  0.27  0.20 
free of disease 
The probabilities  of being cured  by "strip" surgery  are  determined  from the gp52  levels at 
surgery and compared with similar estimations based on the size of the tumor removed. 
* Cure  means that  the animal  remained free of tumors  at the end of the  106-day postsurgery 
observation period. 
S Probability of being free of disease is calculated by determining the number of surviving mice in 
each category (mice remaining tumor free at the end of the observation period) and dividing by 
the total number of mice in each category. 
ing many of the  diagnostic  features of the  mouse mammary  tumor virus.  In 
addition to similar sizes and densities, these include the possession of a reverse 
transcriptase associated with a characteristically large 70S RNA (5, 6) which in 
turn shares detectable sequence homologies (7,  8) with the RNA of the mouse 
mammary tumor virus. In addition, evidence has appeared recently (9) suggest- 
ing that breast cancer patients display cellular hypersensitivity responses to a 
protein of the mouse mammary tumor virus. All of this, along with the informa- 
tion reported here on the mouse mammary tumor model, makes this approach 
towards a specific diagnostic test in the human disease sufficiently plausible to 
warrant continued efforts. 
Summary 
We have previously shown (1, 2) that mice with mammary tumors can always 
be identified by their very high plasma levels of gp52, a 52,000 mol wt glycopro- 
tein of the mouse mammary tumor virus (MMTV).  The present investigation 
demonstrates that the tumor is the principal  source of the plasma gp52 since 
surgical excision is invariably followed in the first 9 days by a sharp decreasing 
(10-100-fold) of the gp52 levels. Control animals in which the tumors were left in 
place  by a  "sham"  surgical  procedure  maintained  their  high  levels  of gp52, 
which continued to increase as the disease progressed. 
The behavior of the gp52 after surgical  removal suggests that gp52 plasma 
concentrations  are diagnostically and prognostically informative,  as indicated 
by the following findings: (a) All tumor recurrences were correctly diagnosed by 
increases in gp52 levels, and some were detected 4-7 days before they were found 
by palpation.  (b) Tumor regrowths were accompanied by continued increases in 
plasma gp52 concentrations  at rates that  usually matched the speed of tumor 
development. (c) The only animals that remained tumor free at the termination 
of the experiment were those that maintained  their gp52 levels at or below 15 E.  RITZI,  D.  S.  MARTIN,  R.  L.  STOLFI,  AND  S.  SPIEGELMAN  1013 
ng/ml. (d) The probability of a tumor-free animal relapsing within 2 wk is much 
higher if its gp52  level is above the  mean.  (e) More remarkably,  the plasma 
levels  of gp52  at  the  time  of surgery are  superior to the  sizes  of the  tumors 
removed as prognostic indicators of eventual surgical "cures." 
The availability of a specific and sensitive systemic measure of disease status 
should augment the usefulness of the murine mammary tumor model by cata- 
lyzing a more rapid acquisition of information on the therapeutic effectiveness of 
the new and varied drug combinations being tested for adjuvant chemotherapy. 
We wish to express our appreciation to L. Stolfi, L. Markovitz, and V. D'Elia for their excellent 
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